Evidence map›Paper›PMID 35895055›Full record

ArticleTranslational vision science & technology2022

The Use of Panitumumab-IRDye800CW in a Novel Murine Model for Conjunctival Squamous Cell Carcinoma.

Gun Min Youn, Ayden G Case, Trent Jarin, BaoXiang Li, Aditi Swarup, Andrea Naranjo, Charbel Bou-Khalil, Jacqueline Yao, Quan Zhou, Marisa E Hom and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational vision science & technology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Evaluation of Pafolacianine (CytaluxMolecular imaging and biology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Gun Min YounStanford University School of Medicine, Stanford, CA, USA.
Ayden G CaseDepartment of Ophthalmology, Stanford University School of Medicine, Stanford, CA, USA.
Trent JarinDepartment of Ophthalmology, Stanford University School of Medicine, Stanford, CA, USA.
BaoXiang LiDepartment of Ophthalmology, Stanford University School of Medicine, Stanford, CA, USA.
Aditi SwarupDepartment of Ophthalmology, Stanford University School of Medicine, Stanford, CA, USA.
Andrea NaranjoDepartment of Ophthalmology, Stanford University School of Medicine, Stanford, CA, USA.
Charbel Bou-KhalilStanford University School of Medicine, Stanford, CA, USA.
Jacqueline YaoDepartment of Ophthalmology, Stanford University School of Medicine, Stanford, CA, USA.
Quan ZhouDepartment of Otolaryngology-Head and Neck Surgery, Stanford Hospital and Clinics, Stanford, CA, USA.
Marisa E HomDepartment of Otolaryngology-Head and Neck Surgery, Stanford Hospital and Clinics, Stanford, CA, USA.
Eben L RosenthalDepartment of Otolaryngology-Head and Neck Surgery, Stanford Hospital and Clinics, Stanford, CA, USA.
Albert Y WuDepartment of Ophthalmology, Stanford University School of Medicine, Stanford, CA, USA.
Stanford University · USStanford Health Care · USTrinity College · USVanderbilt University Medical Center · US

Funding

Stanford Vision Research CoreP30EY026877 · NEI · STANFORD UNIVERSITY · PI Jeffrey L Goldberg · 2017 to 2026
$8.0M
NEI NIH HHS P30 EY026877
6 · The paper itself

Abstract

Purpose: Conjunctival squamous cell carcinoma (SCC) is a sight-threatening ocular surface malignancy with the primary treatment modality being surgical resection. To evaluate surgical imaging modalities to improve surgical resection, we established a novel murine model for conjunctival SCC to demonstrate the utility of panitumumab-IRDye800, a fluorescently labeled anti-epidermal growth factor receptor (EGFR) antibody. Methods: NOD-scid IL2Rgammanull (NSG) mice received subconjunctival injection of UM-SCC-1 or SCC-9, head and neck SCC cell lines. On tumor growth, mice were injected with Panitumumab-IRDye800CW, and imaged with a small animal imaging system and optical coherence tomography (OCT). Immunohistochemistry for SCC markers were used to confirm tumor origin. Results: Seventy-five percent (N = 4) of the UM-SCC-1 group developed aggressive, rapidly growing tumors that were P40 and EGFR positive within two weeks of inoculation. The SCC-9 tumors failed to demonstrate any growth (N = 4). Ocular tumors demonstrated high fluorescence levels with a tumor to background ratio of 3.8. Conclusions: Subconjunctival injections are an appropriate technique to create in vivo models for assessing treatment modalities and novel therapies in conjunctival SCC. Translational Relevance: This model demonstrates Panitumumab-IRDye800CW's utility in the ophthalmic setting and suggests that clinical trials may be warranted.

Indexed as

Conjunctival NeoplasmsHead and Neck NeoplasmsAnimalsAntibodies, MonoclonalCell Line, TumorDisease Models, AnimalErbB ReceptorsMiceMice, Inbred NODPanitumumabSquamous Cell Carcinoma of Head and NeckAntibodies, MonoclonalErbB ReceptorsPanitumumab

Identifiers

PMID35895055
PMCPMC9344218
OpenAlexW4288051136

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.